Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 82

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 82
---
ger. Q.What happens if the Merger is not consummated? If, for any reason, the Merger does not close, Kadimastem will remain an independent public company and will continue to be listed and traded on the Tel Aviv Stock Exchange, or TASE. Kadimastem’s business will not merge with the Merger Sub and become wholly owned by NLS. The Merger Agreement contains customary termination rights for each of NLS and Kadimastem, including the right of NLS and Kadimastem to terminate the Merger Agreement if the Closing shall not have occurred on or before an outside date, which can be extended by mutual agreement. The original outside date included in the Merger Agreement was xv January31, 2024, and has been extended to April30, 2025 and further to June30, 2025, August31, 2025 and October 31, 2025 thereafter by amendments. The Merger Agreement also provides that NLS shall pay to Kadimastem a termination fee of $10,000,000 plus the NLS Operating Expenses (as defined in the Merger Agreement), up to a maximum of $250,000 per month beginning July 28, 2024, and Transaction Expenses (as defined in the Merger Agreement) if NLS terminates the Merger Agreement prior to obtaining the Parent Requisite Vote (as defined in the Merger Agreement) to enter into a definitive agreement providing for a Parent Superior Proposal (as defined in the Merger Agreement) in accordance with the terms of the Merger Agreement. Further, the NLS Board may, following the termination of the Merger Agreement, elect to, among other things, attempt to complete another strategic transaction similar to the Merger, attempt to sell or otherwise dispose of certain assets of NLS or continue to operate the business of NLS. Q.When do you expect the Merger to be completed? The Closing is expected to take place (i) no later than the second business day following the satisfaction or waiver of the conditions described under the section titled “ Conditions to the Consummation of the Merger” beginning on page 159 of this proxy statement/prospectus, or (ii) on such other date as agreed to by the parties to the Merger Agreement in writing, in each case, subject to the satisfaction or waiver of the closing conditions. The Merger Agreement may be terminated by NLS and/or Kadimastem if the Closing has not occurred by October